GeoVax Labs (NASDAQ:GOVX) Earns Buy Rating from D. Boral Capital

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “buy” rating reiterated by D. Boral Capital in a research note issued to investors on Wednesday,Benzinga reports.

Other analysts have also issued research reports about the company. Wall Street Zen lowered GeoVax Labs to a “strong sell” rating in a report on Saturday, January 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GeoVax Labs in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $187.50.

GeoVax Labs Trading Down 3.4%

Shares of GOVX stock opened at $2.88 on Wednesday. GeoVax Labs has a 12 month low of $2.61 and a 12 month high of $56.00. The stock has a market cap of $3.46 million, a P/E ratio of -0.08 and a beta of 3.67. The company has a 50 day simple moving average of $6.73 and a two-hundred day simple moving average of $13.07.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($7.75) earnings per share for the quarter, missing the consensus estimate of ($6.00) by ($1.75). GeoVax Labs had a negative return on equity of 489.67% and a negative net margin of 403.88%. As a group, equities analysts forecast that GeoVax Labs will post -4.49 earnings per share for the current year.

Institutional Trading of GeoVax Labs

Several institutional investors and hedge funds have recently added to or reduced their stakes in GOVX. Jane Street Group LLC bought a new position in GeoVax Labs in the 1st quarter worth approximately $27,000. Sabby Management LLC bought a new position in shares of GeoVax Labs during the third quarter worth $313,000. Armistice Capital LLC bought a new position in shares of GeoVax Labs during the third quarter worth $253,000. Finally, Hudson Bay Capital Management LP purchased a new position in GeoVax Labs during the third quarter valued at $47,000. Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.